// App-Quantinova.ai

5591 : Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).

Researchers

Presenter

  • Alessandro Santin

Principal Investigators

  • Kathleen N. Moore

  • Camille Gunderson

  • Kyle Gowen

  • David Fabrizio

  • Garrett Michael Frampton

  • Jo-Anne Vergilio

  • James Suh

  • Laurie M Gay

  • Shakti Ramkissoon

  • Siraj Mahamed Ali

  • Vincent A. Miller

  • Phil Stephens

  • Jeffrey S. Ross

  • James Sun

  • Julia Andrea Elvin

Medical Centers

  • Yale School of Medicine, Orange, CT

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Foundation Medicine, Inc, Cambridge, MA

  • Foundation Medicine, Inc., Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Foundation Medicine, Inc, Cambridge, MA

  • Albany Medical Center, Albany, NY

Locations

  • United States

Companies

  • Foundation Medicine,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

  • Solid malignancies

Biomarkers

  • Microsatellite instability-high

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved